Have a feature idea you'd love to see implemented? Let us know!

LGND Ligand Pharmaceuticals Inc

Price (delayed)

$110.04

Market cap

$2.01B

P/E Ratio

45.1

Dividend/share

N/A

EPS

$2.44

Enterprise value

$2B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
Ligand Pharmaceuticals's gross margin has increased by 19% YoY
Ligand Pharmaceuticals's quick ratio has surged by 82% YoY but it has decreased by 19% QoQ
Ligand Pharmaceuticals's net income has plunged by 56% from the previous quarter but it has soared by 55% YoY
LGND's P/E is 35% above its last 4 quarters average of 33.5

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
18.27M
Market cap
$2.01B
Enterprise value
$2B
Valuations
Price to book (P/B)
2.55
Price to sales (P/S)
14.86
EV/EBIT
36.66
EV/EBITDA
22.06
EV/Sales
14.98
Earnings
Revenue
$133.48M
EBIT
$54.55M
EBITDA
$90.64M
Free cash flow
-$3.78M
Per share
EPS
$2.44
Free cash flow per share
-$0.21
Book value per share
$43.15
Revenue per share
$7.4
TBVPS
$26.51
Balance sheet
Total assets
$866.41M
Total liabilities
$91.21M
Debt
$7.58M
Equity
$775.2M
Working capital
$293.69M
Liquidity
Debt to equity
0.01
Current ratio
16.82
Quick ratio
15.33
Net debt/EBITDA
-0.12
Margins
EBITDA margin
67.9%
Gross margin
91.8%
Net margin
31.6%
Operating margin
-12.3%
Efficiency
Return on assets
5.1%
Return on equity
5.7%
Return on invested capital
13.9%
Return on capital employed
6.4%
Return on sales
40.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
4.11%
1 week
-1.59%
1 month
8.57%
1 year
106.45%
YTD
54.07%
QTD
9.94%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$133.48M
Gross profit
$122.56M
Operating income
-$16.39M
Net income
$42.14M
Gross margin
91.8%
Net margin
31.6%
The net margin has soared by 109% YoY but it has plunged by 61% from the previous quarter
Ligand Pharmaceuticals's net income has plunged by 56% from the previous quarter but it has soared by 55% YoY
The revenue has declined by 26% year-on-year but it has grown by 13% since the previous quarter
Ligand Pharmaceuticals's gross margin has increased by 19% YoY

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
P/E
45.1
P/B
2.55
P/S
14.86
EV/EBIT
36.66
EV/EBITDA
22.06
EV/Sales
14.98
Ligand Pharmaceuticals's EPS has surged by 55% YoY but it has shrunk by 55% QoQ
LGND's P/E is 35% above its last 4 quarters average of 33.5
LGND's P/B is 50% higher than its last 4 quarters average of 1.7 and 16% higher than its 5-year quarterly average of 2.2
The equity has grown by 17% year-on-year but it has declined by 3.9% since the previous quarter
The price to sales (P/S) is 55% higher than the last 4 quarters average of 9.6 and 52% higher than the 5-year quarterly average of 9.8
The revenue has declined by 26% year-on-year but it has grown by 13% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's ROIC has plunged by 60% from the previous quarter and by 54% YoY
Ligand Pharmaceuticals's return on sales has shrunk by 60% QoQ and by 11% YoY
The ROA has soared by 59% YoY but it has shrunk by 57% QoQ
The company's return on equity has shrunk by 58% QoQ but it rose by 43% YoY

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has surged by 82% YoY but it has decreased by 19% QoQ
LGND's current ratio has soared by 79% year-on-year but it is down by 19% since the previous quarter
The debt is 99% less than the equity
The debt to equity has plunged by 50% YoY
The debt has contracted by 35% YoY but it has grown by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.